Literature DB >> 16181330

Recognition of open conformers of classical MHC by chaperones and monoclonal antibodies.

Ted H Hansen1, Lonnie Lybarger, Lawrence Yu, Vesselin Mitaksov, Daved H Fremont.   

Abstract

There is considerable evidence that the conformation and stability of class I and class II major histocompatibility complex (MHC) proteins is dependent upon high-affinity peptide ligation, but structural data for an empty MHC protein unfortunately is lacking. However, several monoclonal antibodies (mAbs) that specifically detect open MHC conformers have been characterized, and they provide insights into the changes associated with peptide loading and unloading. Here, the structural changes make the argument that certain of these open conformer-specific mAbs recognize analogous MHC segments as the molecular chaperones tapasin and DM. MHC residues located in regions flanking the peptide-terminal anchoring pockets have been implicated in both chaperone and monoclonal antibody binding. Indeed, we propose these regions serve as peptide-binding hinges that are uniquely accessible in open MHC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181330     DOI: 10.1111/j.0105-2896.2005.00315.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  15 in total

1.  A proteasome-dependent, TAP-independent pathway for cross-presentation of phagocytosed antigen.

Authors:  Nawel Merzougui; Roland Kratzer; Loredana Saveanu; Peter van Endert
Journal:  EMBO Rep       Date:  2011-12-01       Impact factor: 8.807

Review 2.  MHC class I antigen presentation: learning from viral evasion strategies.

Authors:  Ted H Hansen; Marlene Bouvier
Journal:  Nat Rev Immunol       Date:  2009-07       Impact factor: 53.106

Review 3.  HLA-DM: arbiter conformationis.

Authors:  Andrea Ferrante
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

4.  The GTPase Rab39a promotes phagosome maturation into MHC-I antigen-presenting compartments.

Authors:  Freidrich M Cruz; Jeff D Colbert; Kenneth L Rock
Journal:  EMBO J       Date:  2019-12-10       Impact factor: 11.598

5.  Molecular and structural determinants of adamantyl susceptibility to HLA-DRs allelic variants: an in silico approach to understand the mechanism of MLEs.

Authors:  Waqasuddin Khan
Journal:  J Comput Aided Mol Des       Date:  2010-11-30       Impact factor: 3.686

6.  Endogenous MHC-related protein 1 is transiently expressed on the plasma membrane in a conformation that activates mucosal-associated invariant T cells.

Authors:  Wei-Jen Chua; Sojung Kim; Nancy Myers; Shouxiong Huang; Lawrence Yu; Daved H Fremont; Michael S Diamond; Ted H Hansen
Journal:  J Immunol       Date:  2011-03-14       Impact factor: 5.422

7.  The peptide-receptive transition state of MHC class I molecules: insight from structure and molecular dynamics.

Authors:  Michael G Mage; Michael A Dolan; Rui Wang; Lisa F Boyd; Maria Jamela Revilleza; Howard Robinson; Kannan Natarajan; Nancy B Myers; Ted H Hansen; David H Margulies
Journal:  J Immunol       Date:  2012-06-29       Impact factor: 5.422

8.  Evidence for a human leucocyte antigen-DM-induced structural change in human leucocyte antigen-DObeta.

Authors:  Francis Deshaies; Djibril A Diallo; Jean-Simon Fortin; Helen M O'Rourke; Abdul Mohammad Pezeshki; Angélique Bellemare-Pelletier; Nicola Raby; Nathalie Bédard; Alexandre Brunet; Lisa K Denzin; Jacques Thibodeau
Journal:  Immunology       Date:  2008-11-14       Impact factor: 7.397

9.  Insights into MHC class I peptide loading from the structure of the tapasin-ERp57 thiol oxidoreductase heterodimer.

Authors:  Gang Dong; Pamela A Wearsch; David R Peaper; Peter Cresswell; Karin M Reinisch
Journal:  Immunity       Date:  2009-01-16       Impact factor: 31.745

10.  Suppression of blastogenesis and proliferation of activated CD4(+) T cells: intravenous immunoglobulin (IVIg) versus novel anti-human leucocyte antigen (HLA)-E monoclonal antibodies mimicking HLA-I reactivity of IVIg.

Authors:  M H Ravindranath; P I Terasaki; T Pham; V Jucaud; S Kawakita
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.